Pharmaceutical Contract Manufacturing Market to Reflect Significant Growth During 2020–2027 | Thermo Fisher Scientific Inc. (US), Catalent, Inc., Lonza Group Ltd, Recipharm AB, Vetter Pharma International GMBH

According to the current analysis of Reports and Data, the global Pharmaceutical Contract Manufacturing market was valued at USD 82430.9 Million in 2018 and is expected to reach USD 144958.8 million by the year 2026, at a CAGR of 7.2%. The pharmaceutical industry uses outsourcing services from providers in the form of contract research organizations (CROs) and contract manufacturing organizations (CMOs). Comprehensive single-source provider from drug development through commercial manufacture has emerged in recent years.

This report covers the recent COVID-19 incidence and its impact on Pharmaceutical Contract Manufacturing Market. The pandemic has widely affected the economic scenario. This study assesses the current landscape of the ever-evolving business sector and the present and future effects of COVID-19 on the market.

Request for a sample copy of this report @ https://www.reportsanddata.com/sample-enquiry-form/2280

The global Pharmaceutical Contract Manufacturing market is highly fragmented with major players Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie Inc. (US), Aenova Group (Germany), Consort Medical plc (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), and Evonik Industries AG (Germany).

It is known as contract research and manufacturing services (CRAMS), or contract development and manufacturing organizations (CDMO). Pharmaceutical Contract Manufacturing organizations are a response to the competitive international nature of the pharmaceutical market as well as the increasing demand for outsourced services.

Further key findings from the report suggest

• Drug development services segment is expected to witness substantial growth of 7.4 % during the forecast period

• The companies operating in the pharmaceutical contract manufacturing market are also acquiring start-ups working on enterprise network equipment technologies to strengthen their product capabilities. For instance, in April 2017, Famar announced the closure of the acquisition of a manufacturing site from Bayer, located at Pointe-Claire, Canada, with the transfer of full ownership of the plant to Famar. Also, in September 2018, Catalent’s acquired Cook Pharmica. The main aim of the acquisition is to strengthen Catalent’s position as a leader in the rapidly growing biologics development, analytical, manufacturing and finished product supply industry by adding more drug substance and drug product expertise and capacity to serve patients worldwide.

• Pharmaceutical Contract manufacturing organizations offer advantages of reduction in overall investment required to bring a new drug product to market, providing access to expensive technologies, quick entry of products in markets, and greater flexibility This has led to several large companies to outsource their biopharmaceutical manufacturing operations

• The deluge of small and virtual startups with negligible manufacturing capacity is flourishing the global pharmaceutical contract manufacturing market. The rising number of U.S. FDA-approved manufacturing facilities in developing countries is also working in favor of the growth of the pharmaceutical contract manufacturing market.

• North America, is the world’s largest market for drug formulations and accounts for almost half of the research and development spending in biotechnology and pharmaceutical markets. Therefore, pharmaceutical contract manufacturing organizations play a major role in this market and have invested in new technologies and facilities to cater to a broad range of outsourcers. The United States is expected to face strong competition from Asia-Pacific contract manufacturing organization providers, especially in solid dosage formulations.

• The consolidation of pharmaceutical contract manufacturing is expected to occur within the next five years, as the competitors will either leave the industry, or abandon a specific area within the industry, or go out of business. This improves the pricing power of value-added Pharmaceutical Contract Manufacturing organizations.

Grab Your Report at an Impressive Discount! Please Click Here @ https://www.reportsanddata.com/discount-enquiry-form/2280

Segments covered in the report

This report forecasts revenue growth at a global, regional & country level, and provides an analysis of the market trends in each of the sub-segments from 2016 to 2026. For the purpose of this study, Reports and Data have segmented the Pharmaceutical Contract Manufacturing market on the basis of service, end-user, and region:

Service Outlook (Revenue in Million USD; 2016–2026)

• Pharmaceutical Manufacturing Services
o Pharmaceutical API Manufacturing
o Pharmaceutical FDF Manufacturing
 Parenteral/Injectable
 Tablet
 Capsule
 Oral Liquid
 Other Formulations
• Biologics Manufacturing Services
o Biologics API Manufacturing
o Biologics FDF Manufacturing
• Drug Development Services

End User Outlook (Revenue in Million USD; 2016–2026)

• Big Pharma
• Small & Mid-size Pharma
• Generic Pharmaceutical Companies
• Other End Users

Regional Outlook (Revenue in Million USD; Volume in Kilotons; 2016–2026)
• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America

Access the Entire Report packed with TOC, Tables and Figures and Outline of Prominent Companies @ https://www.reportsanddata.com/report-detail/pharmaceutical-contract-manufacturing-market

Key selling points of this research study

1. The study gives an in-depth evaluation of the evolving competitive scenario that gives the reader/client a competitive edge.

2. It offers a holistic view of all critical aspects boosting or limiting the growth of the sector

3. The market intelligence report derives an eight-year forecast, including historical, contemporary, and potential market prospects, projecting the estimated progress of the market.

4. It aids informed decision-making by offering an exhaustive database of the pivotal market segments and sub-segments.

Contact Us:

John Watson
Head of Business Development
Reports and Data
40 Wall St. 28th floor New York City, NY 10005 United States
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

This release was published on openPR.